首页> 美国卫生研究院文献>BMC Genetics >Confirmation of warfarin resistance of naturally occurring VKORC1 variants by coexpression with coagulation factor IX and in silico protein modelling
【2h】

Confirmation of warfarin resistance of naturally occurring VKORC1 variants by coexpression with coagulation factor IX and in silico protein modelling

机译:通过与凝血因子IX的共表达和计算机模拟的蛋白来确认天然存在的VKORC1变体对华法林的抗性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundVKORC1 has been identified some years ago as the gene encoding vitamin K epoxide reductase (VKOR) – the target protein for coumarin derivates like warfarin or phenprocoumon. Resistance against warfarin and other coumarin-type anticoagulants has been frequently reported over the last 50 years in rodents due to problems in pest control as well as in thrombophilic patients showing variable response to anticoagulant treatment. Many different mutations have already been detected in the VKORC1 gene leading to warfarin resistance in rats, mice and in humans. Since the conventional in vitro dithiothreitol (DTT)-driven VKOR enzymatic assay often did not reflect the in vivo status concerning warfarin resistance, we recently developed a cell culture-based method for coexpression of VKORC1 with coagulation factor IX and subsequent measurement of secreted FIX in order to test warfarin inhibition in wild-type and mutated VKORC1.
机译:背景几年前,VKORC1被鉴定为编码维生素K环氧还原酶(VKOR)的基因-维生素C的靶蛋白,如华法林或苯丙香豆素。在过去的50年中,由于虫害控制方面的问题以及对抗凝剂治疗表现出不同反应的血栓患者,对华法林和其他香豆素类抗凝剂的耐药性经常被报道。在VKORC1基因中已经检测到许多不同的突变,导致大鼠,小鼠和人类对华法林产生抗药性。由于常规的体外二硫苏糖醇(DTT)驱动的VKOR酶法测定通常不能反映有关华法林耐药性的体内状态,因此我们最近开发了一种基于细胞培养的方法,用于将VKORC1与凝血因子IX共表达,并随后测量分泌的FIX。为了测试华法令在野生型和突变的VKORC1中的抑制作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号